Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx Pharmaceutical (RARE) Investor presentation- Slideshow
06:58pm, Friday, 19'th Nov 2021 Seeking AlphaRock Springs Capital Management LP Buys Baxter International Inc, Warby Parker Inc, Ultragenyx ...
07:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: RARE , ASND , CERE , ACCD , SRRA , MGNX , BAX , WRBY , IMRX , ABOS , AADI , ICVX , BGNE , ARDX , BIIB , BSX , PPD , ADPT ,
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2021 Results - Earnings Call Transcript
11:23pm, Tuesday, 02'nd Nov 2021
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2021 Results - Earnings Call Transcript
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
07:09pm, Tuesday, 02'nd Nov 2021
Ultragenyx (RARE) delivered earnings and revenue surprises of 24.48% and 4.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit
04:05pm, Monday, 25'th Oct 2021
NOVATO, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada
12:41pm, Friday, 08'th Oct 2021
Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 04'th Oct 2021
NOVATO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study
01:54pm, Tuesday, 28'th Sep 2021
Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome after the FDA removes its clinical hold on the sa
NOVATO, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se
Ultragenyx Resumes Dosing Antisense Trial In Rare Neurogenetic Disorder
10:39am, Monday, 27'th Sep 2021
The FDA has removed the clinical hold on GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) GTX-102 trial for Angelman syndrome. The companies can begin dosing naïve
TOKYO--(BUSINESS WIRE)--New data highlighting the sustained benefits of treatment with CRYSVITA® (burosumab) in adults with XLH, a rare genetic metabolic bone disease
NOVATO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and
Ultragenyx to Present at Morgan Stanley Healthcare Conference
04:30pm, Tuesday, 07'th Sep 2021
NOVATO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se
OTTAWA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseas
Ultragenyx to Participate in Panel at Citi's 16th Annual BioPharma Healthcare Conference
04:30pm, Wednesday, 01'st Sep 2021
NOVATO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se
